Utilising peptides derived from healthy human gut microbiome, this technology offers potential therapeutic applications in treating disorders related to mood, behaviour, and gastrointestinal function by modulating the gut-brain axis.
Technology Sectors & Industries
Pharmaceuticals
Filter
Dr Andre Brown
Dr David Riglar
Ryhan Miah
Ryhan is a Junior Officer for Commercialisation at Imperial’s Faculty of Natural Sciences.
Long-lasting nanoparticles for controlled release drug delivery
A nanoparticle drug platform that can deliver small molecule drugs over a sustained period in a stable, low-toxic manner.
Dr Nazila Kamaly
Emeritus Professor Bob Brown
Invariant Natural Killer T cell (iNKT cell) engagers
An immunotherapy platform capable of enhancing the anti-tumour efficacy of invariant natural killer T cells (iNKT).
Lipid Nanoparticle Technologies: Thermostable RNA Formulations
Novel lipid nanoparticles (LNPs) for targeted delivery of RNA-based vaccines and therapeutics, with improved long-term (12 months) thermostability at ambient temperatures (as high as 40 °C), in aqueous liquid or lyophilised form.
Cellular therapy for glaucoma
A cellular therapy to locally deliver nitric oxide (NO) to the conventional aqueous humour outflow pathway, thereby lowering eye pressure and preserving vision in glaucoma.
Sign up for updates
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean nec venenatis arcu. In fermentum non tellus nec vulputate. Integer accumsan, nunc sit amet porta commodo, diam sapien feugiat purus, at imperdiet arcu nisi quis dui. Etiam vel nisl sem. Proin felis nisl, fringilla eu eros ac, sodales pellentesque sem.